Author: pr web

Cellebrite to Release Fourth Quarter and Fiscal Year 2022 Financial Results on February 15, 2023

PETAH TIKVAH, Israel and TYSONS CORNER, Va., Jan. 10, 2023 (GLOBE NEWSWIRE) — Cellebrite DI Ltd. (NASDAQ: CLBT) (the “Company”), a global leader in Digital Intelligence (DI) solutions for the public and private sectors, today announced that it will report its fourth quarter and fiscal year 2022 financial results before market open on Wednesday, February 15, 2023. On that day, management will host a conference call and webcast to discuss the Company’s financial results at 8:30 a.m. ET. Telephone participants are advised to register in advance at: https://register.vevent.com/register/BIa98ecd8f02c04567a1515497e1f850c8. Upon registration, participants will receive a confirmation email detailing how to join

Read More

Zohar Tadmor-Eilat Joins Cellebrite as Chief People Officer

Veteran HR professional brings over 20 years of experience leading business-driven teams CPO Announcement 2023 PETAH TIKVA, Israel and TYSONS CORNER, Va., Jan. 02, 2023 (GLOBE NEWSWIRE) — Cellebrite DI Ltd. (Nasdaq: CLBT), a global leader in Digital Intelligence (DI) solutions for the public and private sectors (“Cellebrite” or “Company”), today announced that Zohar Tadmor-Eilat has been named Chief People Officer (CPO), effective February 1, 2023. Zohar will report to Yossi Carmil, Chief Executive Officer of Cellebrite, and will be a member of the Company’s executive management team. She succeeds Osnat Tirosh, who is leaving Cellebrite after ten years to

Read More

Cellebrite Signs an Over $10 Million Deal with Major West European National Police Force; Marking One of the Largest Digital Intelligence Deals Ever and Further Validating Digital Intelligence as Essential Accelerator for Investigations

The police force will combine Cellebrite’s Pathfinder with existing Cellebrite collect & review solutions to maximize efficiency and resources; also set to provide advanced training PETAH TIKVA, ISRAEL and TYSONS CORNER, Va., Dec. 12, 2022 (GLOBE NEWSWIRE) — Cellebrite DI Ltd. (Nasdaq: CLBT), a global leader in Digital Intelligence (DI) solutions for the public and private sectors, today announced that a European national police force extended its long-term partnership with Cellebrite, resulting in the future deployment of Cellebrite Pathfinder across multiple sites. This significant agreement should enable the police force to deploy Cellebrite’s industry-leading investigative analytics solution across its entire

Read More

Vanderburgh Co. Cyber Crime Task Force and Cellebrite Combine Efforts to Resolve Crimes Quicker and Exonerate the Innocent

Vanderburgh Co. Cyber Crime Task Force makes the most of grant funding to provide the best Digital Intelligence technology to its community PETAH TIKVA, Israel, TYSONS CORNER, Va., and EVANSVILLE, Ind., Nov. 30, 2022 (GLOBE NEWSWIRE) — Cellebrite DI Ltd. (Nasdaq: CLBT), a global leader in Digital Intelligence (DI) solutions for the public and private sectors, today announced the results of its work with the Vanderburgh Co. Cyber Crime Task Force (VCCCTF) to accelerate justice with Cellebrite collect and review solutions. At present, Director Jess Powers’ VCCCTF team utilizes Cellebrite Premium, as well as other Cellebrite collect and review solutions. Director

Read More

Cellebrite Endpoint Inspector Empowers Organizations with Remote Collection of Workplace Applications

Cellebrite now offers a competitive differentiator by offering the ability to collect remote mobile data, remote computer data, and cloud application data in a unified platform PETAH TIKVA, Israel and TYSONS CORNER, Va., Nov. 16, 2022 (GLOBE NEWSWIRE) — Cellebrite DI Ltd. (Nasdaq: CLBT), a global leader in Digital Intelligence (DI) solutions for the public and private sectors, today announced the launch of the cloud workplace app collection, a new Cellebrite Endpoint Inspector capability aimed at improving organizations’ investigation and eDiscovery capabilities by enabling them to collect remote mobile and computer data and cloud workplace application data in a unified

Read More

Cellebrite’s 2022 Industry Trends Survey Reveals the Digital Evidence ‘Tipping Point’ has Been Reached, Creating New Challenges for Law Enforcement Agencies

Digital evidence “more important” than physical evidence and DNA in successfully prosecuting cases New challenges include a growing backlog of devices that are delaying investigations PETAH TIKVAH, Israel and TYSONS CORNER, Va., Nov. 14, 2022 (GLOBE NEWSWIRE) —  Cellebrite DI Ltd. (Nasdaq: CLBT), a global leader in Digital Intelligence (DI) solutions for the public and private sectors, today announced the results of the 2022 Industry Trends Survey. The 2022 Industry Trends Survey, a study commissioned by Cellebrite, reveals that most law enforcement agencies and prosecutors believe that digital evidence is more important than physical evidence and DNA in successfully prosecuting

Read More

Lisa Cole Joins Cellebrite as Chief Marketing Officer

Lisa Cole PETAH TIKVA, Israel and TYSONS CORNER, Va., Oct. 24, 2022 (GLOBE NEWSWIRE) — Cellebrite DI Ltd. (Nasdaq: CLBT), a global leader in Digital Intelligence (DI) solutions for the public and private sectors, today announced Lisa Cole as Chief Marketing Officer (CMO). As CMO for the leading global Digital Intelligence provider, Lisa will be responsible for the company’s overall marketing strategy and execution, which includes brand, public relations, product marketing, demand generation, and marketing operations. “With the recent surge in crime and digital sophistication of criminals at a time of strained budgets and staff, protecting and serving citizens is

Read More

Junshi Biosciences Highlights Pipeline Advances in Immuno-Oncology Through Nearly 40 Data Presentations of Icatolimab and Toripalimab at ASCO 2022

–Favorable preliminary safety and efficacy data for anti-BTLA monoclonal antibody, icatolimab, for the treatment of lymphoma and solid tumors –Toripalimab continues to demonstrate synergy as the cornerstone in innovative combination therapies SHANGHAI, China, June 07, 2022 (GLOBE NEWSWIRE) — Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced today that the company highlighted its pipeline advances in immunotherapy drugs, including anti-PD-1 monoclonal antibody toripalimab and anti-BTLA monoclonal antibody icatolimab (TAB004/JS004), through nearly 40 data presentations at the 2022 American Society of Clinical

Read More

Recent Posts

Categories